EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudieKohortenstudieOpen Access · CC BY 4.0

Piperacillin/tazobactam versus carbapenems for 30-day mortality in patients with ESBL-producing Enterobacterales bloodstream infections: a retrospective, multicenter, non-inferiority, cohort study

Thomas Sahlström Månsson, Alice Askemyr, Torgny Sunnerhagen, Johan Tham, Kristian Riesbeck, Lisa Mellhammar

Infection · 2025

DOI: 10.1007/s15010-025-02496-x ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Infection, 2025. Verfasst von Thomas Sahlström Månsson und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Sahlgrenska University Hospital, Gothenburg, Sweden. Thomas.sahlstrom_mansson@med.lu.se. Hauptthemen laut MEDLINE: Piperacillin, Tazobactam Drug Combination, Carbapenems, Enterobacteriaceae Infections, Anti-Bacterial Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Lund University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Antimicrobial resistance increases with the use of broad-spectrum antibiotics. Studies evaluating antibiotic stewardship are in high demand. Is piperacillin/tazobactam non-inferior to carbapenems regarding 30-day mortality among patients with bloodstream infections caused by extended-spectrum beta-lactamase-producing Enterobacterales?

Methods

This retrospective, multicenter, non-inferiority, cohort study assessed adult patients with bloodstream infections caused by extended-spectrum beta-lactamase-producing Enterobacterales in southern Sweden from 2013 to 2022. Patients were categorized according to the first therapy they received two consecutive doses of (piperacillin/tazobactam or a carbapenem). The primary outcome was 30-day all-cause mortality, measured from when the positive blood cultures were taken. The absolute risk difference for this outcome was calculated for all patients, and two propensity score matched cohorts (empirical and effective), with two different delta limits (5% and 2%). Secondary outcomes included intensive care unit admission, early clinical response, superinfections, relapsed infection and one-year mortality.

Results

A total of 644 patients were included. In the piperacillin/tazobactam group, 26/309 patients met the primary outcome, compared to 27/335 patients in the carbapenem group. The absolute risk difference (-0.4%) was statistically significant in the propensity score matched empirical cohort [1-sided 97.5% confidence interval]: -∞ to 4.0, p = 0.008). Piperacillin/tazobactam was non-inferior to carbapenems for all the secondary outcomes in the same cohort, except for the early clinical response.

Conclusion

Our findings indicate that piperacillin/tazobactam is non-inferior to carbapenems for treating extended-spectrum beta-lactamase-producing Enterobacterales bloodstream infections, with an acceptable 5% increase in 30-day mortality. We suggest that piperacillin/tazobactam should be used more frequently to decrease antimicrobial resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Piperacillin, Tazobactam Drug CombinationCarbapenemsEnterobacteriaceae InfectionsAnti-Bacterial AgentsEnterobacteriaceaeBacteremiaHumansRetrospective StudiesMaleFemaleAgedMiddle Agedbeta-LactamasesSwedenAged, 80 and overCohort StudiesTreatment OutcomeAdult

Stichwörter der Autor:innen

30-day mortalityAntimicrobial resistanceEnterobacteralesExtended-spectrum beta-lactamaseNon-inferiorityPropensity score matching

Substanzen

Piperacillin, Tazobactam Drug CombinationCarbapenemsAnti-Bacterial Agentsbeta-Lactamases

Autor:innen und Institutionen

  • Department of Infectious Diseases, Sahlgrenska University Hospital, Gothenburg, Sweden. Thomas.sahlstrom_mansson@med.lu.se.
  • Department of Translational Medicine, Division of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Lund University, Malmö, Sweden. Thomas.sahlstrom_mansson@med.lu.se.
  • Clinical Research Centre, CRC, Plan 11, Jan Waldenströms Gata 35, Malmö, 205 02, Sweden. Thomas.sahlstrom_mansson@med.lu.se.
  • Department of Clinical Sciences Lund, Division of Infection Medicine, Lund University, Lund, Sweden.
  • Clinical Microbiology, Infection Prevention and Control, Lund, Sweden.
  • Clinical Microbiology, Office for Medical Services, Region Skåne, Kristianstad, Sweden.

Förderung

  • Lund University

Zitieren

APA

Sahlström Månsson, T., Askemyr, A., Sunnerhagen, T., Tham, J., Riesbeck, K., & Mellhammar, L. (2025). Piperacillin/tazobactam versus carbapenems for 30-day mortality in patients with ESBL-producing Enterobacterales bloodstream infections: a retrospective, multicenter, non-inferiority, cohort study. Infection. https://doi.org/10.1007/s15010-025-02496-x

Vancouver

Sahlström Månsson T, Askemyr A, Sunnerhagen T, Tham J, Riesbeck K, Mellhammar L. Piperacillin/tazobactam versus carbapenems for 30-day mortality in patients with ESBL-producing Enterobacterales bloodstream infections: a retrospective, multicenter, non-inferiority, cohort study. Infection. 2025. doi:10.1007/s15010-025-02496-x

BibTeX
@article{SahlstrmMnsson2025,
  author = {Sahlström Månsson, Thomas and Askemyr, Alice and Sunnerhagen, Torgny and Tham, Johan and Riesbeck, Kristian and Mellhammar, Lisa},
  title = {Piperacillin/tazobactam versus carbapenems for 30-day mortality in patients with ESBL-producing Enterobacterales bloodstream infections: a retrospective, multicenter, non-inferiority, cohort study},
  journal = {Infection},
  year = {2025},
  doi = {10.1007/s15010-025-02496-x}
}
Kostenlos starten →